Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling.

Butow, P; Müller, F; Napier, CE; Bartley, N; Ballinger, ML; Biesecker, B; Juraskova, I; Meiser, B; Schlub, TE; Thomas, DM; Goldstein, D; Best, MC; Members of the PiGeOn Project,

Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling.

Butow, P Müller, F Napier, CE Bartley, N Ballinger, ML Biesecker, B Juraskova, I Meiser, B Schlub, TE Thomas, DM Goldstein, D Best, MC Members of the PiGeOn Project,

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Psycho-oncology, 2021, 30, (11), pp. 1920-1929
Issue Date:: 2021-11

Closed Access

	Filename	Description	Size
	Psycho-Oncology - 2021 - Butow - Longitudinal patterns in fear of cancer progression in patients with rare advanced.pdf		286.12 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Butow, P
dc.contributor.author	Müller, F
dc.contributor.author	Napier, CE
dc.contributor.author	Bartley, N
dc.contributor.author	Ballinger, ML
dc.contributor.author	Biesecker, B
dc.contributor.author	Juraskova, I
dc.contributor.author	Meiser, B
dc.contributor.author	Schlub, TE
dc.contributor.author	Thomas, DM
dc.contributor.author	Goldstein, D
dc.contributor.author	Best, MC
dc.contributor.author	Members of the PiGeOn Project,
dc.date.accessioned	2022-01-04T03:16:21Z
dc.date.available	2021-07-05
dc.date.available	2022-01-04T03:16:21Z
dc.date.issued	2021-11
dc.identifier.citation	Psycho-oncology, 2021, 30, (11), pp. 1920-1929
dc.identifier.issn	1057-9249
dc.identifier.issn	1099-1611
dc.identifier.uri	http://hdl.handle.net/10453/152647
dc.description.abstract	Introduction Fear of cancer progression (FCP) impacts quality of life and is a prevalent unmet need in patients diagnosed with advanced cancer, particularly as treatment options are reduced. We aimed to identify longitudinal patterns in FCP over 6 months in patients with advanced cancer receiving comprehensive tumour genomic profiling (CTGP) results, and their correlates. Methods Patients with pathologically confirmed metastatic disease (∼70% rare cancers) receiving or post their last line of standard therapy completed questionnaires at T0 (prior to CTGP), T1 (immediately post CTGP results) and T2 (2 months later). Results High stable (N = 52; 7.3%) and low/moderate stable (N = 56; 7.8%) FCP patterns over time typified the largest participant groups (N = 721). Those with an immediately actionable variant versus a non-actionable variant (p = 0.045), with higher FCP (p < 0.001), and lower Functional Assessment of Chronic Illness Therapy—Spiritual Well-being (FACIT-Sp) scores (p = 0.006) at T0, had higher FCP at T1. Those with higher FCP at T0 (p < 0.001) and at T1 (p < 0.001), lower FACIT-Sp scores at T1 (p = 0.001), lower education (p = 0.031) and female gender (p = 0.027) had higher FCP at T2. Discussion Routine screening for psychological/spiritual characteristics in those about to undergo CTGP may help to identify patients who may benefit from closer monitoring and provision of psychosocial support. Future studies should explore interventions to best address FCP in this vulnerable group, as interventions assessed to date have almost all addressed patients with curative cancers or newly diagnosed advanced disease.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	Psycho-oncology
dc.relation.isbasedon	10.1002/pon.5764
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, 1701 Psychology
dc.subject.classification	Oncology & Carcinogenesis
dc.title	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling.
dc.type	Journal Article
utslib.citation.volume	30
utslib.location.activity	England
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
utslib.for	1701 Psychology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Genetic Counselling
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-01-04T03:16:20Z
pubs.issue	11
pubs.publication-status	Published
pubs.volume	30
utslib.citation.issue	11

Abstract:

Introduction Fear of cancer progression (FCP) impacts quality of life and is a prevalent unmet need in patients diagnosed with advanced cancer, particularly as treatment options are reduced. We aimed to identify longitudinal patterns in FCP over 6 months in patients with advanced cancer receiving comprehensive tumour genomic profiling (CTGP) results, and their correlates. Methods Patients with pathologically confirmed metastatic disease (∼70% rare cancers) receiving or post their last line of standard therapy completed questionnaires at T0 (prior to CTGP), T1 (immediately post CTGP results) and T2 (2 months later). Results High stable (N = 52; 7.3%) and low/moderate stable (N = 56; 7.8%) FCP patterns over time typified the largest participant groups (N = 721). Those with an immediately actionable variant versus a non-actionable variant (p = 0.045), with higher FCP (p < 0.001), and lower Functional Assessment of Chronic Illness Therapy—Spiritual Well-being (FACIT-Sp) scores (p = 0.006) at T0, had higher FCP at T1. Those with higher FCP at T0 (p < 0.001) and at T1 (p < 0.001), lower FACIT-Sp scores at T1 (p = 0.001), lower education (p = 0.031) and female gender (p = 0.027) had higher FCP at T2. Discussion Routine screening for psychological/spiritual characteristics in those about to undergo CTGP may help to identify patients who may benefit from closer monitoring and provision of psychosocial support. Future studies should explore interventions to best address FCP in this vulnerable group, as interventions assessed to date have almost all addressed patients with curative cancers or newly diagnosed advanced disease.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/152647